Agape ATP Corp

Análisis de la acción Agape ATP Corp (ATPC)

$1.370

+0.131 (+9.59%)Al cierre

Loading chart…
Máximo
1.425
Apertura
1.320
Precio medio ponderado por volumen
1.36
Volumen
12.22K
Capitalización
—
Mínimo
1.280
Importe
16.60K
EV/EBITDA, TTM
0.00

Agape ATP Corporation is a Malaysia-based investment holding company. The principal activity of the Company is to supply health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging, and products designed to improve the overall health system of the human body, along with various wellness programs. The Company offers three series of programs, each consisting of different services and products: ATP Zeta Health Program, ENERGETIQUE, and BEAUNIQUE. Its ATP Zeta Health Program is a health program designed to assist in the elimination of various diseases caused by environmental pollutants, unhealthy dietary intake, and unhealthy lifestyles. The ENERGETIQUE series consists of energy mask series, hyaluronic acid, and mousse facial cleanser. Its BEAUNIQUE product series focuses on researching diet’s impact on modifying gene expressions to address genetic variations and deliver a nutrigenomic solution for every individual.

Análisis de IA of Agape ATP Corp (ATPC)

Vender

Agape ATP Corp (ATPC) is not a good buy right now due to its significant price decline and poor financial performance. The current price is $1.25, which is 97.97% lower than its 1-year high of $73.50. The RSI is at 33.51, indicating that the stock is oversold but lacks momentum for recovery. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth expectations, and the gross margin is only 85.96%, which, while high, is overshadowed by the company's overall financial instability. The main risk is the 76.19% year-to-date decline, indicating severe market sentiment against the stock.

Métricas de valoración

El PER previsto actual de Agape ATP Corp (ATPC) es 0.00, frente a su media de 5 años de 0.00.

PER previsto

Muy infravalorado
Media 5A P/E
0.00
P/E actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
0.00
EV/EBITDA actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
0.00
P/S actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Escenarios de precio de Alphio AI para ATPC

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%ATPC

$1.53

Precio del escenario

B

Base

Base · 50%ATPC

$1.40

Precio del escenario

B

Bajista

Bajista · 25%ATPC

$1.25

Precio del escenario

Cronología de eventos

2026-03-12 (ET)

09:20:00

Agape ATP Regains Nasdaq Listing Compliance

2026-03-10 (ET)

09:30:00

AGAPE ATP Enters Collaboration Agreement with Citadel Investment

2026-02-09 (ET)

20:00:00

Agape ATP Corp Trading Halted, News Pending

2026-02-06 (ET)

13:40:00

Agape ATP Files $200M Mixed Securities Shelf

2026-02-05 (ET)

09:10:00

Agape ATP Corporation Faces Potential Nasdaq Delisting

Noticias

Preguntas frecuentes sobre ATPC, respondidas por Alphio AI

Agape ATP Corporation is a Malaysia-based investment holding company. The principal activity of the Company is to supply health and wellness products, including supplements to assist in cell metabolism, detoxification, blood circulation, anti-aging, and products designed to improve the overall health system of the human body, along with various wellness programs. The Company offers three series of programs, each consisting of different services and products: ATP Zeta Health Program, ENERGETIQUE, and BEAUNIQUE. Its ATP Zeta Health Program is a health program designed to assist in the elimination of various diseases caused by environmental pollutants, unhealthy dietary intake, and unhealthy lifestyles. The ENERGETIQUE series consists of energy mask series, hyaluronic acid, and mousse facial cleanser. Its BEAUNIQUE product series focuses on researching diet’s impact on modifying gene expressions to address genetic variations and deliver a nutrigenomic solution for every individual. It operates in the Healthcare sector.

Agape ATP Corp (ATPC) is not a good buy right now due to its significant price decline and poor financial performance. The current price is $1.25, which is 97.97% lower than its 1-year high of $73.50. The RSI is at 33.51, indicating that the stock is oversold but lacks momentum for recovery. Furthermore, the forward P/E ratio is 0, suggesting no earnings growth expectations, and the gross margin is only 85.96%, which, while high, is overshadowed by the company's overall financial instability. The main risk is the 76.19% year-to-date decline, indicating severe market sentiment against the stock.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar